Mouse treatment


The effects of experimental treatments and genetic interventions (gene knockout) on the course of infection and pathology in murine malaria models are listed in this part of the database. For each molecule, data about the genetic background of the mouse strain (and number of backcrosses), parasite species, inoculum size (pRBC), details of the treatment/knockout, effect on parasitemia, pathology and survival, additional data of the effects of the treatments (e.g. on expression of other factors), references (Refs), and a hyperlink to the original paper in the PubMed database (U.S. National Library of Medicine, National Institutes of Health) is included.

Dynamic fields: these are the columns that you can select to show in the output table. See also "How to use MalarImDB?" for more information.

Abbreviations: ALI, acute lung injury; anti-…; treatment with depleting antibodies; CM, experimental cerebral malaria (when indicated the incidence is included between brackets, e.g. CM (100%) means that 100% of the mice suffered from cerebral pathology); EG, experimental group; HP&A, hyperparasitemia and anemia; i.p., intraperitoneal administration; MA-ARDS, malaria-associated acute respiratory distress syndrome; N.I., not indicated; p.o., oral administration; r, recombinant; R, receptor; s, soluble; male mice; female mice; -/-, gene knockout mice; +, and/positive (example1: rIL-1a + anti-IFN-g: mice were treated with recombinant IL-1a and antibodies to deplete IFN-g; example2: CD4+ T cells, CD4 positive T cells); ↑, increased; ↓, decreased; ~, on average

 

SelectField
Full
Molecular group
Molecule/Cell
Plasmodium strain
pRBC infection titer
Mouse genetic background (Con)
Level of backcrossing
Experimental treatment group (EG)
Lethal infection (Con)
Lethal infection (EG)
Pathology (Con)
Pathology (EG)
Parasitemia (EG vs Con)
Additional phenotypes (EG vs Con)
Refs
PubMed
Execute an advanced search by using AND or OR between terms
Full Molecule/Cell Plasmodium strain Mouse genetic background (Con) Experimental treatment group (EG) Lethal infection (Con) Lethal infection (EG) Pathology (Con) Pathology (EG) Parasitemia (EG vs Con) Additional phenotypes (EG vs Con) Refs PubMed
uPA receptor (uPAR, CD87) Plasmodium berghei ANKA C57BL/6 x 129/Sv uPAR -/- N.I. N.I. N.I. N.I. N.I. ↑ splenomegaly; similar LN cellularity; no significant apoptosis in white pulp (spleen) and LN Piguet et al., 2001, Dev Immunol
Urokinase plasminogen activator (uPA) Plasmodium berghei ANKA C57BL/6 x 129/Sv uPA -/- yes yes CM (90%) CM (30%) Similar Prolonged survival (~1 week); ↓ thrombocytopenia Piguet et al., 2000, Infect Immun
Va14+ NKT cell Plasmodium berghei ANKA C57BL/6 Ja281 -/- yes yes CM (100%) CM (100%) Similar Delayed onset of disease symptoms (~ 2 days) Hansen et al., 2003, Immunity
Va14+ NKT cell Plasmodium berghei K173 C57BL/6 Ja281 -/- N.I. N.I. N.I. N.I. N.I. Similar plasma IFN-g and splenic IFN-g mRNA expression 24h p.i. Mitchell et al., 2005, Infect Immun

Pages

CSV